Ergot alkaloid glycosides with immunomodulatory activities
Language English Country Great Britain, England Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
8818236
DOI
10.1016/0968-0896(96)00074-0
PII: 0968-0896(96)00074-0
Knihovny.cz E-resources
- MeSH
- Adjuvants, Immunologic chemistry pharmacology MeSH
- Killer Cells, Natural drug effects immunology MeSH
- Cytotoxicity, Immunologic drug effects MeSH
- Ergolines chemistry MeSH
- Glycosides chemistry pharmacology MeSH
- Rats MeSH
- Cells, Cultured MeSH
- Humans MeSH
- Magnetic Resonance Spectroscopy MeSH
- Molecular Sequence Data MeSH
- Tumor Cells, Cultured MeSH
- Ergot Alkaloids chemistry pharmacology MeSH
- Carbohydrate Sequence MeSH
- Spectrometry, Mass, Fast Atom Bombardment MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Adjuvants, Immunologic MeSH
- elymoclavine MeSH Browser
- Ergolines MeSH
- Glycosides MeSH
- lysergol MeSH Browser
- Ergot Alkaloids MeSH
New glycosides derived from ergot alkaloids elymoclavine and DH-lysergol were synthesized by chemoenzymatic methods. beta-Glucosides were obtained either by chemical method or by transglycosylation (glycosidase from Aspergillus oryzae), lactosides were prepared by further extension of carbohydrate chain using beta-1,4-galactosyltransferase (bovine milk) and alpha-5-N-acetylneuraminyl-(2-->6)-beta-D-galactopyranosyl-(l-->4)-2- acetamido-2-deoxy-beta-D-glucopyranosyl-(1-->O)-elymoclavine was prepared using alpha-2,6-sialyltransferase (rat liver). Immunomodulatory activity of elymoclavine and 9,10-dihydrolysergol and their glycosylated derivatives on natural killer (NK) cell-mediated cytotoxicity of human resting and activated human peripheral blood mononuclear cells (PBMC) was investigated. Addition of ergot alkaloid glycosides to the mixtures of effector and target cells potentiated the PBMC cytotoxicity against both NK-sensitive and -resistant target cells. The glycoconjugates of elymoclavine enhanced cytotoxicity of PBMC against NK-resistant target cells. The glycoconjugates of DH-lysergol potentiated NK cytotoxicity of PBMC against NK-sensitive target cells.
References provided by Crossref.org
Compounds isolated at the Institute of Microbiology in 1989-2001 and future trends
